Sugi Predict

Sugi Predict / Compounds / SCHEMBL983847

SCHEMBL983847

SCHEMBL983847

COc1ccc(CC(=O)O)c(Br)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 0.65
▸ AKR1C2 P52895 3/20 0.56
▸ AKR1C3 P42330 3/20 0.56
▸ PTGS1 P23219 2/20 0.56
▸ KDM4E B2RXH2 3/20 0.55
▸ POLB P06746 2/20 0.53
▸ LCK P06239 1/20 0.52
▸ ABL1 P00519 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ RIN1 Q13671 1/20 0.47
▸ CTDSP1 Q9GZU7 1/20 0.47
▸ MMP2 P08253 2/20 0.47
▸ MMP12 P39900 2/20 0.47
▸ MMP8 P22894 1/20 0.47
▸ MMP13 P45452 1/20 0.47
▸ MMP14 P50281 1/20 0.47
▸ MMP16 P51512 1/20 0.47
▸ LMNA P02545 1/20 0.45
▸ MMP9 P14780 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2742615 0.88 HSD17B10 (0.68) HSD17B10AKR1C2AKR1C3PTGS1KDM4E
Bromide SCHEMBL29853696 0.86 HSD17B10 (0.66) HSD17B10AKR1C2AKR1C3PTGS1KDM4E
SCHEMBL27557248 0.86 CYP3A4 (0.49) HSD17B10AKR1C2AKR1C3PTGS1KDM4E
SCHEMBL1097958 0.84 HSD17B10 (0.46) HSD17B10AKR1C2AKR1C3PTGS1KDM4E
SCHEMBL26824456 0.84 PLA2G2A (0.48) HSD17B10AKR1C2AKR1C3PTGS1POLB
SCHEMBL2436724 0.84 ALDH1A1 (0.54) HSD17B10AKR1C2AKR1C3PTGS1KDM4E
SCHEMBL30046118 0.84 ALDH1A1 (0.54) HSD17B10AKR1C2AKR1C3PTGS1KDM4E
SCHEMBL8637464 0.84 HSD17B10 (0.46) HSD17B10AKR1C2AKR1C3PTGS1KDM4E
SCHEMBL30335932 0.84 POLB (0.73) HSD17B10AKR1C2AKR1C3PTGS1KDM4E
SCHEMBL3296862 0.84 POLB (0.73) HSD17B10AKR1C2AKR1C3PTGS1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293522-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-09-21 — — US disclosed
US-20230293522-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-09-21 — — US disclosed
US-20230293522-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-09-21 — — US disclosed
CN-116675642-A Preparation method of chiral aporphine alkaloid 智简生物科技(上海)有限公司 2023-09-01 — — CN disclosed
WO-2023155873-A1 CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF IN PHARMACEUTICS 江苏恒瑞医药股份有限公司 2023-08-24 — — WO disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
CN-114524798-B Benzodithiocarbazaheterocycle derivative and preparation method and application thereof 华南师范大学 2023-04-07 — — CN disclosed
WO-2023010000-A1 COMPOUNDS AND METHODS FOR TREATING 5-HT2 RESPONSIVE CONDITIONS BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2023-02-02 — — WO disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 — — CN disclosed
US-20070299069-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 — — US disclosed
US-20070299069-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 — — US disclosed
US-20070299069-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 — — US disclosed
US-20070299068-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 — — US disclosed
US-20070299068-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 — — US disclosed
US-20070299068-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 — — US disclosed
WO-2007084413-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 — — WO disclosed
WO-2007084435-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 — — WO disclosed
CN-1897950-A Fused aryl and heteroaryl derivatives and methods of use thereof WYETH CORP (US) 2007-01-17 — — CN disclosed
US-20060189606-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2006-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB HSD17B10 1370/4885AKR1C2 2879/4885AKR1C3 3263/4885
US-20070299068-A1 Methods for treating hepatitis C HAVCR2, EIF2AK2, MAVS HSD17B10 1276/4885AKR1C2 2273/4885AKR1C3 1781/4885
US-20230293522-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME SAE1, SUMO1, SUMO3 HSD17B10 1241/4885AKR1C2 1910/4885AKR1C3 1254/4885
US-20060189606-A1 Methods for treating hepatitis C HAVCR2, EIF2AK2, MAVS HSD17B10 1276/4885AKR1C2 2273/4885AKR1C3 1781/4885
US-20070299069-A1 Methods for treating hepatitis C HAVCR2, EIF2AK2, MAVS HSD17B10 1276/4885AKR1C2 2273/4885AKR1C3 1781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.